SARS-CoV-2 antibodies and breakthrough infections in the Virus Watch cohort
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
SARS-CoV-2 antibodies and breakthrough infections in the Virus Watch cohort
Authors
Keywords
-
Journal
Nature Communications
Volume 13, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-08-19
DOI
10.1038/s41467-022-32265-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Vaccines Elicit Highly Conserved Cellular Immunity to SARS-CoV-2 Omicron
- (2022) Jinyan Liu et al. NATURE
- The T cell immune response against SARS-CoV-2
- (2022) Paul Moss NATURE IMMUNOLOGY
- Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant
- (2022) Yu Gao et al. NATURE MEDICINE
- Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines
- (2022) Jia Wei et al. NATURE MEDICINE
- Evolution of antibody immunity to SARS-CoV-2
- (2021) Christian Gaebler et al. NATURE
- Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19
- (2021) Adam K. Wheatley et al. Nature Communications
- Longitudinal analysis reveals that delayed bystander CD8+ T cell activation and early immune pathology distinguish severe COVID-19 from mild disease.
- (2021) Laura Bergamaschi et al. IMMUNITY
- Differential T cell reactivity to endemic coronaviruses and SARS-CoV-2 in community and health care workers
- (2021) Ricardo da Silva Antunes et al. JOURNAL OF INFECTIOUS DISEASES
- Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum
- (2021) Chang Liu et al. CELL
- Vaccinations Against COVID-19 May Have Averted Up To 140,000 Deaths In The United States
- (2021) Sumedha Gupta et al. HEALTH AFFAIRS
- Spike-antibody waning after second dose of BNT162b2 or ChAdOx1
- (2021) Madhumita Shrotri et al. LANCET
- Infections, hospitalisations, and deaths averted via a nationwide vaccination campaign using the Pfizer–BioNTech BNT162b2 mRNA COVID-19 vaccine in Israel: a retrospective surveillance study
- (2021) Eric J Haas et al. LANCET INFECTIOUS DISEASES
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months
- (2021) Stephen J. Thomas et al. NEW ENGLAND JOURNAL OF MEDICINE
- Integrated longitudinal immunophenotypic, transcriptional, and repertoire analyses delineate immune responses in patients with COVID-19
- (2021) Samuele Notarbartolo et al. Science Immunology
- Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2
- (2021) Leo Swadling et al. NATURE
- Children develop robust and sustained cross-reactive spike-specific immune responses to SARS-CoV-2 infection
- (2021) Alexander C. Dowell et al. NATURE IMMUNOLOGY
- Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection
- (2021) Shuo Feng et al. NATURE MEDICINE
- Waning Immunity after the BNT162b2 Vaccine in Israel
- (2021) Yair Goldberg et al. NEW ENGLAND JOURNAL OF MEDICINE
- Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection
- (2021) Ital Nemet et al. NEW ENGLAND JOURNAL OF MEDICINE
- Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar
- (2021) Hiam Chemaitelly et al. NEW ENGLAND JOURNAL OF MEDICINE
- Test-Negative Designs
- (2019) Jan P. Vandenbroucke et al. EPIDEMIOLOGY
- Theoretical Basis of the Test-Negative Study Design for Assessment of Influenza Vaccine Effectiveness
- (2016) Sheena G. Sullivan et al. AMERICAN JOURNAL OF EPIDEMIOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now